Table 2.
Dose of lanthanum carbonate at the end of the dose-titration phase; safety set
Dose, mg/day | Dose-titration phase (n= 39) |
Parallel-group phase |
|
---|---|---|---|
Lanthanum carbonate (n= 10) | Placebo (n= 11) | ||
375 |
5 (12.8) |
1 (10.0) |
0 (0.0) |
750 |
11 (28.2) |
3 (30.0) |
4 (36.4) |
1500 |
14 (35.9) |
3 (30.0) |
4 (36.4) |
2250 | 9 (23.1) | 3 (30.0) | 3 (27.3) |
Data are presented as n (%).